Hopp til hovedinnhold

Legemiddelbehandling av demens

Legemiddelbehandling av demens er legemidler som kan bedre noen av symptomene ved Alzheimers demens. Dette er legemidler som kan ha en liten, men positiv effekt på kognitiv funksjon, oppmerksomhet, initiativ og hukommelse hos noen av pasientene.

Sist revidert:

QR
Del pasientinformasjon

Den ligger åpent tilgjengelig på NHI.no sammen annen relevant informasjon

https://nhi.no/sykdommer/eldre/demens/demens-legemiddler/ 

Generelt

Donepezil (Donepezil, Aricept)

Rivastigmin (Rivastigmin, Exelon)

Galantamin (Galantamin, Reminyl)

Memantin (Memantin, Ebixa, eller Nemdatine)

Vurdering av effekt

Vil du vite mer?

Kilder

Referanser

Dette dokumentet er basert på det profesjonelle dokumentet Demens ved Alzheimers sykdom. Referanselisten for dette dokumentet vises nedenfor.

  1. Helsedirektoratet. Demens. Nasjonal faglig retningslinje. Først publisert 16.08.2017. Sist faglig oppdatert 03.01.2020. www.helsedirektoratet.no 
  2. McKhann GM, Knopman DS, Chertkow H, et al.. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7(3): 263-9. pmid:21514250 PubMed 
  3. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging 1997; 18(4 Suppl): S1. pmid:9330978 PubMed 
  4. Alzheimer A. Uber eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift fur Psychiatrie und Psychisch-Gerichtliche Medizin. 1907. 64: 146-148.
  5. Bowler JV. Modern concept of vascular cognitive impairment. Br Med Bull 2007; 83: 291-305. pmid:17675645 PubMed 
  6. Hunskår S (red.). Allmennmedisin. S. 419. Gyldendal Norsk Forlag AS. Gyldendal Akademisk, 2003.
  7. Gjøra L, Kjelvik G, Strand BH, et al. Forekomst av demens i Norge. Utgitt av Forlaget aldring og helse 2020. ISBN 978-82-8061-579-4 (PDF). butikk.aldringoghelse.no 
  8. Seshadri, S, Beiser, A, Kelly-Hayes, M, Kase, CS, Au, R et al. The lifetime risk of stroke: estimates from the Framingham Study. Stroke 2006; 37(2): 345-50. PMID: 16397184 PubMed 
  9. Nasjonal kompetansetjeneste for aldring og helse: Fakta om demens. www.aldringoghelse.no 
  10. Scheltens P, Blennow K, Breteler MM, et al. Alzheimer's disease. Lancet. 2016 Jul 30;388(10043):505-17. Epub 2016 Feb 24.pmid: 26921134 PubMed 
  11. Small GW, Siddarth P, Ercoli LM, et al.. Healthy behavior and memory self-reports in young, middle-aged, and older adults. Int Psychogeriatr 2013; 25(6): 981-9. pmid:23425438 PubMed 
  12. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Biol. 2011 Sep. 3(9):a006189.
  13. Haass C, De Strooper B. Review: neurobiology - the presenilins in Alzheimer's disease - proteolysis holds the key. Science 1999; 286: 916-19. PubMed 
  14. Green RC, Schneider LS, Amato DA, et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: A randomized controlled trial. JAMA 2009; 302: 2557-64. Journal of the American Medical Association 
  15. Shea YF, Chu LW, Chan AO, et al.. A systematic review of familial Alzheimer's disease: Differences in presentation of clinical features among three mutated genes and potential ethnic differences. J Fomos Med Assoc 2016 Feb; 115(2): 67-75. pmid:26337232 PubMed 
  16. Naj AC, Schellenberg GD, ADGC. Genomic variants, genes, and pathways of Alzheimer's disease: An overview. Am J Med Genet B Neuropsychiatr Genet 2017 Jan; 174(1): 5-26. pmid:27943641 PubMed 
  17. Schellenberg GD, Montine TJ. The genetics and neuropathology of Alzheimer’s disease. Acta Neuropathol 2012; 124(3): 305-23. pmid:22618995 PubMed 
  18. Dupuy AM, Mas E, Ritchie K, et al. The relationship between Apolipoprotein E4 and lipid metabolism is impaired in Alzheimer's disease. Gerontology 2001; 47: 213-18. PubMed 
  19. Tang MX, Jacobs D, Stern Y, et al. Effects of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996; 348: 429-32. PubMed 
  20. Jonsson T, Stefansson H, Steinberg S, et al. Variant of TREM2 associated with rhe risk of Alzheiemer's disease. N Engl J Med 2012. doi:10.1056/NEJMoa1211103 DOI 
  21. Øksengård AR, Engedal K. Arvelige forhold ved Alzheimers sykdom. Tidsskr Nor Lægeforen 2002; 122: 530-1. Tidsskrift for Den norske legeforening 
  22. Haas JG, Lathe R. Microbes and Alzheimer's Disease: New Findings Call for a Paradigm Change. Trends Neurosci 2018; 41: 570-3. pmid:30033181 PubMed 
  23. Lollis SS, Valdes PA, Li Z, Ball PA, Roberts DW. Cause-specific mortality among neurosurgeons. J Neurosurg 2010; 113: 474-8. pmid:20170305 PubMed 
  24. Norton MC, Smith KR, Østbye T. Greater risk of dementia when spouse has dementia? The Cache County study. J Am Geriatr Soc. 2010;58:895-900. pmid:20722820 PubMed 
  25. Elmer WA, Kumar DK, Shanmugam NK, et al. Alzheimer's disease-associated β-amyloid is rapidly seeded by herpesviridae to protect against brain infection. Neuron. 2018;99:56-63.e3. pmid:30001512 PubMed 
  26. Sochocka M, Zwolińska K, Leszek J. The Infectious Etiology of Alzheimer's Disease. Curr Neuropharmacol. 2017;15(7):996-1009. PMID: 28294067 PubMed 
  27. Truelsen T, Thudium D, Grønbaek M. Amount and type of alcohol and risk of dementia: the Copenhagen City Heart Study. Neurology 2002; 59: 1313-9. Neurology 
  28. Tasaki S, Gaiteri C, Mostafavi S, et al. The Molecular and Neuropathological Consequences of Genetic Risk for Alzheimer's Dementia. Front Neurosci 2018; 12: 699. doi:10.3389/fnins.2018.00699. Pmid: 30349450 PubMed 
  29. Jones EL, Mok K, Hanney M, et al. Evidence that PICALM affects age at onset of Alzheimer's dementia in Down syndrome. Neurobiol Aging 2013; 34(10): 2441.e1-5. pmid:23601808 PubMed 
  30. Livingston G, Huntley J, et.al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. The Lancet 2020 Aug 8;396(10248):413-446. Pmid: 32738937.
  31. Coupland CAC, Hill T, Dening T, et al. Anticholinergic Drug Exposure and the Risk of Dementia A Nested Case-Control Study. JAMA Intern Med 2019; 179: 1084-93. pmid:31233095 PubMed 
  32. Cheng HT, Lin FJ, Erickson SR, et al. The Association Between the Use of Zolpidem and the Risk of Alzheimer's Disease Among Older People. J Am Geriatr Soc. 2017. PMID: 28884784 PubMed 
  33. Jayadevappa R, Chhatre S, Malkowicz B, et al. Association Between Androgen Deprivation Therapy Use and Diagnosis of Dementia in Men With Prostate Cancer. JAMA Netw Open 2019; 2: e196562. pmid:31268539 PubMed 
  34. Sachdeva A, Chandra M, Choudhary M, et al. Alcohol-Related Dementia and Neurocognitive Impairment: A Review Study. Int J High Risk Behav Addict 2016 ; 5(3): e27976. pmid:27818965 PubMed 
  35. Hill NL, Mogle J. Alzheimer's disease risk factors as mediators of subjective memory impairment and objective memory decline: protocol for a construct-level replication analysis. BMC Geriatr 2018; 18(1): 260. pmid:30373526 PubMed 
  36. Snowden JS, Thompson JC, Stopford CL, et al. The clinical dianosis of early-onset dementias: diagnostic accuracy and clinicopathological relationships. Brain 2011; : doi: 10.1093/brain/awr189.
  37. Palmer K, Bäckman L, Winblad B, Fratiglioni L. Detection of Alzheimer's disease and dementia in the preclinical phase: population based cohort stud. BMJ 2003; 326: 245-50. British Medical Journal 
  38. Malek-Ahmadi M, Davis K, Belden C, et al. Validation and diagnostic accuracy of the Alzheimer's questionnaire. Age Ageing 2012; 41(3): 396-9. pmid:22367356 PubMed 
  39. Arevalo-Rodriguez I, Smailagic N, Roque I Figuls M, et al. Mini-Mental State Examination (MMSE) for the detection of Alzheimer`s disease and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2015 Mar 5;3:CD010783. doi: 10.1002/14651858.CD010783.pub2 DOI 
  40. Creavin ST, Wisniewski S, Noel-Storr AH, Trevelyan CM, Hampton T, Rayment D, Thom VM, Nash KJE, Elhamoui H, Milligan R, Patel AS, Tsivos DV, Wing T, Phillips E, Kellman SM, Shackleton HL, Singleton GF, Neale BE, Watton ME, Cullum S. Mini-Mental State Examination (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and over in community and primary care populations. Cochrane Database of Systematic Reviews 2016, Issue 1. Art. No.: CD011145. DOI: 10.1002/14651858.CD011145.pub2 DOI 
  41. Pietroboni AM, Scarioni M, Carandini T, et al.. CSF β-amyloid and white matter damage: a new perspective on Alzheimer's disease. J Neurol Neurosurg Psychiatry 2017 ; Epub Oct 20: jnnp-2017-316603. pmid:29054920 PubMed 
  42. Knapskog A-B, Engedal K, Selbæk G, Øksengård A-R. Alzheimers sykdom – diagnostikk og behandling. Tidsskr Nor Legeforen 2021. doi:10.4045/tidsskr.20.0919 DOI 
  43. Øksengård AR, Haakonsen M, Dullerud R, Babovic A, Laake K, Engedal K. Bildediagnostiske metoder ved demensutredning. Tidsskr Nor Lægeforen 2002; 122: 710-4. Tidsskrift for Den norske legeforening 
  44. Johnson KA, Schultz A, Betensky RA, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol 2016 Jan; 79(1): 110-9. pmid:26505746 PubMed 
  45. Goldman JS. Genetic testing and counseling in the diagnosis and management of young-onset dementias. Psychiatr Clin North Am 2015; 38(2): 295-308. pmid:25998117 PubMed 
  46. National Institute for Health and Care Excellence (NICE). Dementia: assessment, management and support for people living with dementia and their carers. NICE guideline [NG97] Published date: June 2018 www.nice.org.uk 
  47. Merkuri N, Croy A, Henry S, et al. Comparing and benchmarking national dementia strategies and policies European Dementia Monitor 2017. Alzheimer Europe, 2017
  48. Walsh S, King E, Brayne C. France removes state funding for dementia drugs. BMJ 2019; 367: I6930. doi:10.1136/bmj.l6930 DOI 
  49. Husebo BS, Ballard C, Sandvik R, Nilsen OB, Aarsland D. Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial. BMJ 2012; 343: d4065. BMJ (DOI) 
  50. Russ TC, Morling JR. Cholinesterase inhibitors for mild cognitive impairment. Cochrane Database of Systematic Reviews 2012; 9: CD009132. Cochrane (DOI) 
  51. Tricco AC, Soobiah C, Berliner S, et al. Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: a systematic review and meta-analysis. CMAJ 2013; 185: 1393-401. pmid:24043661 PubMed 
  52. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database of Systematic Reviews 2006; 1: CD005593. Cochrane (DOI) 
  53. Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 2008; 148: 379-97. Annals of Internal Medicine 
  54. Soysal P, Isik AT, Stubbs B, et al. Acetylcholinesterase inhibitors are associated with weight loss in older people with dementia: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2016 Jun 3 . pmid:27261502 PubMed 
  55. Årsland D, Engedal KA, Nygaard HA, Louhija J, Ulstein I, Holm M. Bruk av kolinesterasehemmere. Tidsskr Nor Lægeforen 2003; 123: 1500-3. PubMed 
  56. Landmark K, Reikvam Å. Kolinesterasehemmere mot demens - nyttig i klinisk praksis?. Tidsskr Nor Legeforen 2008; 128: 294-7. tidsskriftet.no 
  57. Howard RJ, Juszczak E, Ballard CG, et al. Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med 2007; 357: 1382-92. PubMed 
  58. Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med 2012; 366: 957-9. New England Journal of Medicine 
  59. Mueller C, Perera G, Hayes RD, et al. Associations of acetylcholinesterase inhibitor treatment with reduced mortality in Alzheimer`s disease: a retrospective survival analysis. Age Ageing. 2017; 24: 1-7. PMID: 28655175 PubMed 
  60. Qizilbash N. Treatment of Alzheimer's disease. I: Qizilbash N, Schneider L, Chui H, Tariot P, Brodaty H, Kaye J et al. Evidence-based dementia practice. Oxford: Blackwell Science, 2002: 467 - 588.
  61. Birks JS, Grimley Evans J. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev. 2015 ;4:CD001191. PMID: 25858345. PubMed 
  62. Statens legemiddelverk. Terapianbefaling. Nytt om legemidler 2003; 26, nr. 6: 10-6.
  63. O'Brien JT, Ballard CG. Drugs for Alzheimer's disease (ed). BMJ 2001; 323: 123-4. PubMed 
  64. Engedal K, Brækhus A, Gjerstad L. Effekt av legemidler mot demens. Tidsskr Nor Lægeforen 2004; 124: 1641-2. PubMed 
  65. Wilkinson D, Wirth Y, Goebel C. Memantine in patients with moderate to severe Alzheimer's disease: meta-analyses using realistic definitions of response. Dement Geriatr Cogn Disord. 2014;37(1-2):71-85. doi: 10.1159/000353801 DOI 
  66. Winblad B, Poritis N. Memantine in severe dementia: result of the 9M-best study. Int J Geriatr Psychiatry 1999; 14: 135 - 46. PubMed 
  67. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database of Systematic Reviews 2006, Issue 2. Art. No.: CD003154. DOI: 10.1002/14651858.CD003154.pub5. DOI 
  68. Schneider LS, Dagerman KS, Higgins JPT, McShane R. Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol 2011; e-pub.
  69. Lopez OL, Becker JT, Wahed AS. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry 2009; 80: 600-7. PubMed 
  70. Farrimond LE, Roberts E, McShane R. Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review. BMJ 2012; 2: e000917. doi:10.1136/bmjopen-2012-000917 DOI 
  71. Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD003120. DOI: 10.1002/14651858.CD003120.pub3. DOI 
  72. Vellas B, Coley N, Ousset PJ, et al. Long-term use of standardised ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol 2012. doi:10.1016/S1474-4422(12)70206-5 DOI 
  73. DeKosky ST, Williamson JD, Fitzpatrick AL et al. Ginkgo biloba for prevention of dementia. JAMA 2008; 300:2253-62. Journal of the American Medical Association 
  74. Snitz BE, O'Meara ES, Carlson MC, et al. Ginkgo biloba for preventing cognitive decline in older adults. JAMA 2009; 302: 2663-70. Journal of the American Medical Association 
  75. Ruths S, Straand J. Antipsykotiske midler mot uro ved demens - medisinsk behandling eller kjemisk atferdsregulering?. Tidsskr Nor Lægeforen 2005; 125: 1672-5. PubMed 
  76. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294: 1934-43. Journal of the American Medical Association 
  77. Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer`s disease. N Engl J Med. 2006; 355: 1525-38. PubMed 
  78. Douglas IJ, Smeeth L. Exposure to antipsychotics and risk of stroke: self controlled case series study. BMJ 2008; 337: a1227. BMJ (DOI) 
  79. Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009; 360: 225-35. New England Journal of Medicine 
  80. Ooms S, Ju YE. Treatment of Sleep Disorders in Dementia. Curr Treat Options Neurol 2016; 18(9): 40. pmid:27476067 PubMed 
  81. Cao B, Rosenblat JD, Brietzke E, et al. Comparative efficacy and acceptability of antidiabetic agents for Alzheimer`s disease and mild cognitive impairment: A systematic review and network meta-analysis. Diabetes Obes Metab. 2018. PMID: 29790638 PubMed 
  82. Bentham P, Gray R, Sellwold E, et al. Aspirin in Alzheiemer's disease (AD 2000): a randomised open-label trial. Lancet Neurol 2008; 7: 41-9. PubMed 
  83. Aisen PS, Schneider LS, Sano M, et al. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease. JAMA 2008; 300: 1774-83. Journal of the American Medical Association 
  84. Malouf R, Grimley Evans J. Folic acid with or without vitamin B12 for the prevention and treatment of healthy elderly and demented people. Cochrane Database Syst Rev 2008; 8: CD004514. Cochrane (DOI) 
  85. Dysken MW, Sano M, Asthana S, et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease. JAMA 2014; 311: 33-44. doi:10.1001/jama.2013.282834 DOI 
  86. Farina N, Llewellyn D, Isaac MGEKN, et al. Vitamin E for Alzheimer`s dementia and mild cognitive impairment. Cochrane Database Syst Rev. 2017; 4: CD002854. PMID: 28418065 PubMed 
  87. Roy S, Weinstock JL, Ishino AS, et al.. Association of Cognitive Impairment in Patients on 3-Hydroxy-3-Methyl-Glutaryl-CoA Reductase Inhibitors. J Clin Med Res 2017 Jul; 9(7): 638-649. pmid:28611866 PubMed 
  88. Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab inmild-to-moderate Alzheimer's disease. N Engl J Med 2013; 370: 322-33. New England Journal of Medicine 
  89. Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 2014; 370: 311-21. New England Journal of Medicine 
  90. Burckhardt M, Herke M, Wustmann T, et al. Omega-3 fatty acids for the treatment of dementia. Cochrane Database Syst Rev 2016 11;4:CD009002 Cochrane (DOI) 
  91. Sydenham E, Dangour AD, Lim WS. Omega 3 fatty acid for the prevention of cognitive decline and dementia. Cochrane Database of Systematic Reviews 2012, Issue 6. Art. No.: CD005379. DOI: 10.1002/14651858.CD005379.pub3 DOI 
  92. Atri A, Frölich L, Ballard C, et al. Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease Three Randomized Clinical Trials. JAMA 2018; 319: 130-42. pmid:29318278 PubMed 
  93. Kehoe PG, Turner N, Howden B, et al. Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol 2021. doi:10.1016/S1474-4422(21)00263-5 DOI 
  94. Graff MJ, Vernooij-Dassen MJ, Thijssen M et al. Community based occupational therapy for patients with dementia and their care givers: randomised controlled trial. BMJ 2006; 333: 1196 201.
  95. Guure CB, Ibrahim NA, Adam MB, et al. Impact of Physical Activity on Cognitive Decline, Dementia, and Its Subtypes: Meta-Analysis of Prospective Studies. Biomed Res Int 2017; 9016924: Epub Feb 7. pmid:28271072 PubMed 
  96. Brodaty H, Arasaratnam C. Meta-analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia. Am J Psychiatry 2012; 169: 946-53. PMID: 22952073 PubMed 
  97. Huntley JD, Gould RL, Liu K, et al. Do cognitive interventions improve general cognition in dementia? A meta-analysis and meta-regression. BMJ Open. 2015 Apr 2;5(4):e005247. doi: 10.1136/bmjopen-2014-005247 DOI 
  98. Woods B, Aguirre E, Spector AE, Orrell M. Cognitive stimulation to improve cognitive functioning in people with dementia. Cochrane Database of Systematic Reviews 2012, Issue 2. Art. No.: CD005562. DOI: 10.1002/14651858.CD005562.pub2. DOI 
  99. Brækhus A. Belastning hos pårørende til pasienter med demenssykdom. DiA, demens i allmennpraksis; 2000: 4.
  100. Waldorff FB, Buss DV, Eckermann A, et al. Efficacy of psychosocial intervention in patients with mild Alzheimer`s disease: the multicentre, rater blinded, randomised Danish Alzheimer Intervention Study (DAISY). BMJ 2012; 345: e4693. BMJ (DOI) 
  101. Livingston G, Kelly L, Lewis-Holmes E, et al. Non-pharmacological interventions for agitation in dementia: systematic review of randomised controlled trials. BJPsych 2014. doi:10.1192/bjp.bp.113.141119 DOI 
  102. Chang YS, Chu H, Yang CY, et al. The efficacy of music therapy for people with dementia: A meta-analysis of randomised controlled trials. J Clin Nurs 2015. doi:10.1111/jocn.12976 DOI 
  103. Forrester LT, Maayan N, Orrell M, et al. Aromatherapy for dementia. Cochrane Database of Syst Rev 2014; 2: CD003150. doi:10.1002/14651858.CD003150.pub2 DOI 
  104. Helsedirektoratet. Anbefalinger om kosthold, ernæring og fysisk aktivitet. Rapport IS-2170, 2014 www.helsedirektoratet.no 
  105. Verghese J, Lipton RB, Katz MJ, et al. Leisure activities and the risk of dementia in the elderly. N Engl J Med 2003; 348: 2508-16. New England Journal of Medicine 
  106. Dhana K, Evans DA, Rajan KB, Bennett DA, Morris MC. Healthy lifestyle and the risk of Alzheimer dementia: Findings from 2 longitudinal studies. Neurology. 2020 Jun 17:10.1212/WNL.0000000000009816. doi: 10.1212/WNL.0000000000009816. PMID: 32554763. PubMed 
  107. Dhana K, Franco OH, Ritz EM, et al. Healthy lifestyle and life expectancy with and without Alzheimer’s dementia: population based cohort study. BMJ 2022; 377: e068390. pmid:35418416 PubMed 
  108. Ryan J, Storey E, Murray AM, et al. Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline. Neurology. 2020 Mar 25. pii: WNL.0000000000009277 PMID: 32213642 PubMed 
  109. McGuinness B, Craig D, Bullock R, et al. Statins for the prevention of dementia. Cochrane Database Syst Rev. 2016 Jan 4;1:CD003160. doi: 10.1002/14651858.CD003160.pub3 DOI 
  110. Panegyres PK, Frencham K. Course and causes of suspected dementia in young adults: a longitudinal study. Am J Alzheimers Dis Other Demen 2007; 22(1): 48-56. pmid:17534002 PubMed 
  111. Nicastro N, Assal F, Seeck M. From here to epilepsy: the risk of seizure in patients with Alzheimer's disease. Epileptic Disord 2016 Mar; 18(1): 1-12. pmid:26907471 PubMed 
  112. Ljøstad U, Myglånd Å. Alzheimer demens. NEL Nevrologi. Sist oppdatert 24.10.2018. nevro.legehandboka.no
  113. Xie J, Brayne C, Matthews FE, for the Medical Research Council Cognitive Function and Ageing Study collaborators. Survival times in people with dementia: Analysis from population based cohort study with 14 year follow-up. BMJ 2008; 336: 225-6. British Medical Journal 
  114. Larson EB, Shadlen MF, Wang L. Survival after initial diagnosis of Alzheimer disease. Ann Intern Med 2004; 140: 501-09.
  115. Peters ME, Schwartz S, Han D, et al. Neuropsychiatric Symptoms as Predictors of Progression to Severe Alzheimer's Dementia and Death: The Cache County Dementia Progression Study. Am J Psychiatry 2015. pmid:25585033 PubMed